Medigus Ltd (NASDAQ: MDGS) has announced that its wholly-owned subsidiary, Charging Robotics Ltd., has successfully completed a proof of concept showing its EV wireless charging robot’s capabilities.
Charging Robotics to solve EV wireless charging challenges
Charging Robotics is looking to overcome the EV wireless charging challenges of highly efficient, seamless battery for unmanned and manned vehicles. Its demonstration system comprises a robotic platform with autonomous navigation capability. Also, a second system component is an EV simulating unit housing target batteries, supporting electronics, and an energy receiving coil.
Interestingly the robot is navigated from the home position on a predefined path to the starting point, which is close to the optimal charging point. Most importantly, charging occurs at a maximum rate if there is a perfect alignment of both coils once the energy is transmitted from the transmitting to the receiving coil.
Polyrizon releases study results showing its tech can prevent COVID-19.
Medigus has announced that privately held Polyrizon, which holds 33.24%, is developing biological gels to protect patients against external pathogens and biological threats, had reported pre-clinical data from the previously announced pre-clinical trial. The results showed that the company’s novel tech could reduce the infection risk with the coronavirus and prevent SARS-CoV-2. Polyrizon’s tech comprises bio gel that can be applied topically for dry and wet administration.
For one month, the study was conducted in Israel tested various formulations of highly differentiated bio gel relative to control groups for protection against COVID-19. Data from the cell-culture study confirms that the novel product works in a dose-dependent way to minimize cell infection from the SARS-CoV-2 virus that infects humans. In addition, the company tested various prototypes of its flagship platform against coronaviruses. In the studies, the products showed high-efficiency over-controlled groups in preventing COVID-19 from damaging epithelial host cells and through cell death inhibition.
